PT  - JOURNAL ARTICLE
AU  - El-Medany, Ahmed
AU  - Adams, Zoe H
AU  - Blythe, Hazel C
AU  - Hope, Katrina A
AU  - Kendrick, Adrian H
AU  - Abdala Sheikh, Ana Paula
AU  - Paton, Julian FR
AU  - Nightingale, Angus K
AU  - Hart, Emma C
TI  - Carotid body dysregulation contributes to the enigma of long COVID
AID  - 10.1101/2023.05.25.23290513
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.05.25.23290513
4099  - http://medrxiv.org/content/early/2023/06/03/2023.05.25.23290513.short
4100  - http://medrxiv.org/content/early/2023/06/03/2023.05.25.23290513.full
AB  - The symptoms of long COVID, which include fatigue, breathlessness, dysregulated breathing, and exercise intolerance, have unknown mechanisms. These symptoms are also observed in heart failure and are partially driven by increased sensitivity of the carotid chemoreflex. As the carotid body has an abundance of ACE2 (the cell entry mechanism for SARS-CoV-2), we investigated whether carotid chemoreflex sensitivity was elevated in participants with long COVID. During cardiopulmonary exercise testing, the VE/VCO2 slope (a measure of breathing efficiency) was higher in the long COVID group than in the controls, indicating excessive hyperventilation. The hypoxic ventilatory response, which measures carotid chemoreflex sensitivity, was increased in long COVID participants and correlated with the VE/VCO2 slope, suggesting that excessive hyperventilation may be related to carotid body hypersensitivity. Therefore, the carotid chemoreflex is sensitized in long COVID and may explain dysregulated breathing and exercise intolerance in these participants. Tempering carotid body excitability may be a viable treatment option for long COVID patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Elizabeth Blackwell Institute, University of Bristol and the Bristol and Weston Hospitals Charity pump priming scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study was granted by South Central Hampshire NHS Research Ethics Committee (21/SC/0260) and the Health Research AuthorityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the author